Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Other Accumulated Expenses (2020 - 2022)

Kiora Pharmaceuticals' Other Accumulated Expenses history spans 3 years, with the latest figure at $15630.0 for Q3 2022.

  • For Q3 2022, Other Accumulated Expenses changed N/A year-over-year to $15630.0; the TTM value through Sep 2022 reached $15630.0, changed N/A, while the annual FY2021 figure was $28961.0, 77.33% down from the prior year.
  • Other Accumulated Expenses reached $15630.0 in Q3 2022 per KPRX's latest filing, down from $28961.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $127730.0 in Q4 2020 to a low of $15630.0 in Q3 2022.
  • Average Other Accumulated Expenses over 3 years is $57440.3, with a median of $28961.0 recorded in 2021.
  • The largest YoY upside for Other Accumulated Expenses was 77.33% in 2021 against a maximum downside of 77.33% in 2021.
  • A 3-year view of Other Accumulated Expenses shows it stood at $127730.0 in 2020, then plummeted by 77.33% to $28961.0 in 2021, then crashed by 46.03% to $15630.0 in 2022.
  • Per Business Quant, the three most recent readings for KPRX's Other Accumulated Expenses are $15630.0 (Q3 2022), $28961.0 (Q4 2021), and $127730.0 (Q4 2020).